Baseline characteristics and lung function at initiation of nintedanib
| Patients | 126 |
| Age (years) | 60±13 |
| Baseline lung function | |
| FVC (L) (n=103) | 1.86±0.70 |
| FVC (% pred) (n=102) | 57.62±18.56 |
| DLCO (% pred) (n=79) | 32.66±11.04 |
| KCO (% pred) (n=74) | 65.85±18.97 |
| Gender | |
| Male | 59 (47) |
| Female | 67 (53) |
| ILD diagnosis | |
| fHP | 44 (34.9) |
| CTD-ILD | 44 (34.9) |
| Unclassifiable IIP | 9 (7.1) |
| Fibrotic NSIP | 8 (6.3) |
| Fibrotic OP | 4 (3.2) |
| PPFE | 3 (2.4) |
| Asbestosis | 3 (2.4) |
| Smoking-related ILD | 3 (2.4) |
| Familial PF | 1 (0.8) |
| Fibrotic sarcoid | 1 (0.8) |
| DIP | 1 (0.8) |
| HIV-associated ILD | 1 (0.8) |
| Other | 4 (3.2) |
| Smoking status | |
| Current smoker | 2 (1.6) |
| Ex-smoker | 46 (36.5) |
| Never-smoker | 63 (50) |
| No data | 15 (11.9) |
| Hospital | |
| Guy's and St Thomas' NHS Foundation trust | 10 (7.9) |
| Manchester University NHS Foundation Trust | 13 (10.3) |
| North Bristol NHS Trust | 3 (2.4) |
| Oxford University Hospital | 16 (12.7) |
| Royal Papworth Hospital | 15 (11.9) |
| Royal Brompton Hospital | 61 (48.4) |
| Royal Devon and Exeter Hospital | 4 (3.2) |
| University Hospital Birmingham | 4 (3.2) |
| MRC dyspnoea score | |
| 1 | 4 (3) |
| 2 | 18 (14) |
| 3 | 26 (21) |
| 4 | 27 (21) |
| 5 | 16 (13) |
| No data | 35 (28) |
| Home oxygen (ambulatory/LTOT) | |
| Yes | 79 (62.7) |
| No | 45 (35.7) |
| Unknown | 2 (1.6) |
| Fibrotic pattern on CT | |
| UIP | 30 (24) |
| Non-UIP | 95 (75) |
| No data | 1 (0.8) |
| Indication for starting nintedanib | |
| Progressive symptoms | 111 (88) |
| Lung function decline | 100 (79) |
| CT progression | 85 (67) |
| Concurrent immunosuppression | |
| Yes | 113 (90) |
| No | 13 (10) |
| Prednisolone | 86 (68) |
| Mycophenolate mofetil | 70 (56) |
| Azathioprine | 6 (5) |
| Hydroxychloroquine | 13 (10) |
| Leflunomide | 3 (2) |
| Rituximab | 9 (7) |
| Tacrolimus | 1 (0.8) |
| Methotrexate | 3 (2) |
| Change in immunosuppression following nintedanib initiation | |
| Unchanged | 76 (60) |
| Increased | 29 (23) |
| Decreased | 13 (10) |
| Other | 8 (6) |
Data are presented as n, mean±sd or n (%). FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: transfer coefficient of the lung for carbon monoxide; ILD: interstitial lung disease; fHP: fibrotic hypersensitivity pneumonitis; CTD-ILD: connective tissue disease-associated ILD; IIP: idiopathic interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; OP: organising pneumonia; PPFE: pleuroparenchymal fibroelastosis; PF: pulmonary fibrosis; DIP: desquamative interstitial pneumonia; NHS: National Health Service; MRC: Medical Research Council; LTOT: long-term oxygen therapy; CT: computed tomography; UIP: usual interstitial pneumonia.